Clinical Context
A patient with advanced or metastatic HER2-low or HER2-positive solid tumor (commonly breast cancer) presents to the oncology infusion center for systemic therapy. The oncologist has prescribed datopotamab deruxtecan-dlnk administered intravenously; billing uses J9011 charged per 1 mg vial. The typical workflow: pre-infusion nursing assessment (vital signs, review of allergies, baseline labs including CBC, CMP, and LFTs), verification of chemotherapy orders and weight-based dosing, pharmacy preparation and verification of J9011 under sterile compounding protocols, and administration via peripheral IV or implanted central venous access by an oncology infusion nurse. Observation for infusion-related reactions and post-infusion monitoring for potential adverse events (eg, neutropenia, interstitial lung disease/pneumonitis, hepatic toxicity) occur in the infusion suite. Documentation includes diagnosis, dose in mg, number of vials, lot number, route, start/stop times, site of service (typically outpatient hospital-based infusion center or physician office infusion suite), and any applicable modifier to reflect unusual circumstances (eg, discontinued service, drug wastage, patient tolerance issues). Typical payors involved include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, and Medicare for authorization, coverage, and payment adjudication.